Adverse reactions of ferric carboxymaltose

Harish Thanusubramanian, Navin Patil, Smitha Shenoy, K. L. Bairy, Yashdeep Sharma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The author reports a 55-year-old female diagnosed of chronic kidney disease grade-5 with associated co-morbidities like type 2 diabetes mellitus, diabetic retinopathy and hypothyroidism was admitted for arteriovenous fistula construction. She was started on ferric carboxymaltose for the treatment of anaemia. She was given a test dose before administering the drug intravenously and she did not develop any reaction. The drug ferric carboxymaltose was then administered over a period of one hour. About half an hour after drug administration, the patient developed breathlessness and myalgia. After half hour of the above episode of breathlessness and myalgia. She also developed vomiting (one episode). Patient was managed with oxygen therapy, IV fluids and other drugs like corticosteroids, phenaramine maleate and nalbuphine which controlled the above symptoms.

Original languageEnglish
Pages (from-to)HD01-HD02
JournalJournal of Clinical and Diagnostic Research
Volume8
Issue number10
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Myalgia
Pharmaceutical Preparations
Dyspnea
Nalbuphine
Fluid Therapy
Arteriovenous Fistula
Diabetic Retinopathy
Medical problems
Hypothyroidism
Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
Vomiting
Anemia
Adrenal Cortex Hormones
Oxygen
Morbidity
Fluids
ferric carboxymaltose
Therapeutics
maleic acid

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Thanusubramanian, Harish ; Patil, Navin ; Shenoy, Smitha ; Bairy, K. L. ; Sharma, Yashdeep. / Adverse reactions of ferric carboxymaltose. In: Journal of Clinical and Diagnostic Research. 2014 ; Vol. 8, No. 10. pp. HD01-HD02.
@article{c93b415acc874aa59045133d553a0d89,
title = "Adverse reactions of ferric carboxymaltose",
abstract = "The author reports a 55-year-old female diagnosed of chronic kidney disease grade-5 with associated co-morbidities like type 2 diabetes mellitus, diabetic retinopathy and hypothyroidism was admitted for arteriovenous fistula construction. She was started on ferric carboxymaltose for the treatment of anaemia. She was given a test dose before administering the drug intravenously and she did not develop any reaction. The drug ferric carboxymaltose was then administered over a period of one hour. About half an hour after drug administration, the patient developed breathlessness and myalgia. After half hour of the above episode of breathlessness and myalgia. She also developed vomiting (one episode). Patient was managed with oxygen therapy, IV fluids and other drugs like corticosteroids, phenaramine maleate and nalbuphine which controlled the above symptoms.",
author = "Harish Thanusubramanian and Navin Patil and Smitha Shenoy and Bairy, {K. L.} and Yashdeep Sharma",
year = "2014",
month = "1",
day = "1",
doi = "10.7860/JCDR/2014/9499.5015",
language = "English",
volume = "8",
pages = "HD01--HD02",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "10",

}

Adverse reactions of ferric carboxymaltose. / Thanusubramanian, Harish; Patil, Navin; Shenoy, Smitha; Bairy, K. L.; Sharma, Yashdeep.

In: Journal of Clinical and Diagnostic Research, Vol. 8, No. 10, 01.01.2014, p. HD01-HD02.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse reactions of ferric carboxymaltose

AU - Thanusubramanian, Harish

AU - Patil, Navin

AU - Shenoy, Smitha

AU - Bairy, K. L.

AU - Sharma, Yashdeep

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The author reports a 55-year-old female diagnosed of chronic kidney disease grade-5 with associated co-morbidities like type 2 diabetes mellitus, diabetic retinopathy and hypothyroidism was admitted for arteriovenous fistula construction. She was started on ferric carboxymaltose for the treatment of anaemia. She was given a test dose before administering the drug intravenously and she did not develop any reaction. The drug ferric carboxymaltose was then administered over a period of one hour. About half an hour after drug administration, the patient developed breathlessness and myalgia. After half hour of the above episode of breathlessness and myalgia. She also developed vomiting (one episode). Patient was managed with oxygen therapy, IV fluids and other drugs like corticosteroids, phenaramine maleate and nalbuphine which controlled the above symptoms.

AB - The author reports a 55-year-old female diagnosed of chronic kidney disease grade-5 with associated co-morbidities like type 2 diabetes mellitus, diabetic retinopathy and hypothyroidism was admitted for arteriovenous fistula construction. She was started on ferric carboxymaltose for the treatment of anaemia. She was given a test dose before administering the drug intravenously and she did not develop any reaction. The drug ferric carboxymaltose was then administered over a period of one hour. About half an hour after drug administration, the patient developed breathlessness and myalgia. After half hour of the above episode of breathlessness and myalgia. She also developed vomiting (one episode). Patient was managed with oxygen therapy, IV fluids and other drugs like corticosteroids, phenaramine maleate and nalbuphine which controlled the above symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84907861469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907861469&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2014/9499.5015

DO - 10.7860/JCDR/2014/9499.5015

M3 - Article

VL - 8

SP - HD01-HD02

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 10

ER -